Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Echec-MAT antibiotic combination for previable threatened late miscarriage with intact membranes
2023-505500-37-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clarithromycin, metronidazole and ceftriaxone in late miscarriage (LM) and Cervical insufficiency (CI) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Primary composite endpoint, Late miscarriage and 6 more. Planned start Sep 2024; status: authorised.
02
Drugs
clarithromycinmetronidazoleceftriaxone
03
Conditions
late miscarriage (LM)Cervical insufficiency (CI)
Beyond the preview
Go deeper on 2023-505500-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505500-37-00.